SG10201808038TA - Sildenafil Solutions and Methods of Making and Using Same - Google Patents

Sildenafil Solutions and Methods of Making and Using Same

Info

Publication number
SG10201808038TA
SG10201808038TA SG10201808038TA SG10201808038TA SG10201808038TA SG 10201808038T A SG10201808038T A SG 10201808038TA SG 10201808038T A SG10201808038T A SG 10201808038TA SG 10201808038T A SG10201808038T A SG 10201808038TA SG 10201808038T A SG10201808038T A SG 10201808038TA
Authority
SG
Singapore
Prior art keywords
methods
sildenafil
making
same
sildenafil citrate
Prior art date
Application number
SG10201808038TA
Inventor
Moshe Rogosnitzky
Morris Aboohi
Original Assignee
Vigorous Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201808038T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vigorous Solutions Ltd filed Critical Vigorous Solutions Ltd
Publication of SG10201808038TA publication Critical patent/SG10201808038TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q5/00—Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
    • H01Q5/50—Feeding or matching arrangements for broad-band or multi-band operation
    • H01Q5/55—Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/27—Adaptation for use in or on movable bodies
    • H01Q1/28—Adaptation for use in or on aircraft, missiles, satellites, or balloons
    • H01Q1/288—Satellite antennas
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith

Abstract

SILDENAFIL SOLUTIONS AND METHODS OF MAKING AND USING SAME The invention relates to compositions containing dissolved sildenafil citrate and methods of producing such compositions, wherein sildenafil citrate is dissolved in water mixed with one or more alcohols, and optionally a ketone may be used to enhance solubility. 5 It also relates to methods of using such compositions containing dissolved sildenafil citrate utilizing dosages significantly below existing therapeutic dosages of sildenafil citrate. No Figure to Accompany
SG10201808038TA 2014-03-19 2015-03-19 Sildenafil Solutions and Methods of Making and Using Same SG10201808038TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461955299P 2014-03-19 2014-03-19

Publications (1)

Publication Number Publication Date
SG10201808038TA true SG10201808038TA (en) 2018-10-30

Family

ID=54145440

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201607507VA SG11201607507VA (en) 2014-03-19 2015-03-19 Sildenafil solutions and methods of making and using same
SG10201808038TA SG10201808038TA (en) 2014-03-19 2015-03-19 Sildenafil Solutions and Methods of Making and Using Same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201607507VA SG11201607507VA (en) 2014-03-19 2015-03-19 Sildenafil solutions and methods of making and using same

Country Status (24)

Country Link
US (2) US9968609B2 (en)
EP (2) EP3372083A1 (en)
JP (1) JP6744821B2 (en)
KR (1) KR20160137584A (en)
CN (1) CN106132204B (en)
AU (2) AU2015233006B2 (en)
CA (1) CA2942628C (en)
CL (1) CL2016002318A1 (en)
CY (1) CY1120187T1 (en)
DK (1) DK3119201T3 (en)
EA (1) EA032819B1 (en)
ES (1) ES2668915T3 (en)
HR (1) HRP20180773T1 (en)
HU (1) HUE038431T2 (en)
IL (1) IL247840B (en)
LT (1) LT3119201T (en)
MX (1) MX371276B (en)
NO (1) NO2723977T3 (en)
PL (1) PL3119201T3 (en)
PT (1) PT3119201T (en)
RS (1) RS57206B1 (en)
SG (2) SG11201607507VA (en)
SI (1) SI3119201T1 (en)
WO (1) WO2015140748A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2723977T3 (en) 2014-03-19 2018-03-10
JP6902372B2 (en) * 2017-02-28 2021-07-14 ヱスビー食品株式会社 Composition for suppressing bitterness
SG11202006080SA (en) 2017-12-26 2020-07-29 Ftf Pharma Private Ltd Liquid oral formulations for pde v inhibitors
EP3956024A4 (en) * 2019-04-18 2023-01-11 Ellamed IP & Services Pte. Ltd. Liquid sildenafil citrate compositions
EP4058026A4 (en) * 2019-11-12 2023-12-06 American Regent, Inc. Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
WO1994017675A1 (en) * 1993-02-05 1994-08-18 Kao Corporation Taste modifying method and bitter taste reducing method
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
WO2001035926A2 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
KR100848344B1 (en) 2000-02-04 2008-07-25 유서홍 Preparation of aqueous clear solution dosage forms with bile acids
EP1301186A1 (en) 2000-07-19 2003-04-16 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US20030216407A1 (en) 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
EP1781239A2 (en) 2003-11-17 2007-05-09 Patus Ltd Compositions effective in altering the perception of malodor
JP2007517803A (en) 2004-01-05 2007-07-05 テバ ファーマシューティカル インダストリーズ リミティド Method for producing sildenafil base and citrate
CN1925860A (en) * 2004-01-05 2007-03-07 特瓦制药工业有限公司 Methods for the production of sildenafil base and citrate salt
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
PE20061107A1 (en) 2005-03-14 2006-12-08 Wyeth Corp TIGECYCLINE COMPOSITIONS AND METHODS FOR ITS PREPARATION
US7556487B2 (en) 2006-03-29 2009-07-07 Intergum Gida Sinayi ve Ticaret A.S. Apparatus for making center-filled chewing gum pieces
FR2906140B1 (en) * 2006-09-22 2008-12-05 Philippe Perovitch GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS
DE502008002360D1 (en) 2007-06-19 2011-03-03 Symrise Ag Aroma composition for reducing or suppressing undesirable bitter and astringent impression
EP2072044A1 (en) * 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising a liquid or flowable core composition
WO2009125415A1 (en) 2008-04-07 2009-10-15 Hetero Research Foundation Amorphous form of sildenafil citrate
FR2939321B1 (en) 2008-12-05 2011-08-26 Philippe Perovitch DEVICE FOR CONDITIONING AND ADMINISTERING ACTIVE INGREDIENTS IN HYDRO ALCOHOLIC SOLUTION
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
DE102010049708A1 (en) * 2010-10-28 2012-05-03 Hexal Ag Oral pharmaceutical film formulation for bitter-tasting drugs
CA2858364C (en) * 2011-12-05 2018-07-24 Foye Opawale Oral spray formulations and methods for administration of sildenafil
GB2497933B (en) 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
EP2849738B1 (en) * 2012-05-16 2023-12-06 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
NO2723977T3 (en) 2014-03-19 2018-03-10

Also Published As

Publication number Publication date
DK3119201T3 (en) 2018-05-28
HRP20180773T1 (en) 2018-06-15
HUE038431T2 (en) 2018-10-29
CA2942628C (en) 2022-06-07
CY1120187T1 (en) 2018-12-12
EA032819B1 (en) 2019-07-31
IL247840B (en) 2019-03-31
LT3119201T (en) 2018-05-10
KR20160137584A (en) 2016-11-30
AU2018250378B2 (en) 2020-05-14
AU2015233006B2 (en) 2018-07-19
SG11201607507VA (en) 2016-10-28
WO2015140748A2 (en) 2015-09-24
ES2668915T3 (en) 2018-05-23
CA2942628A1 (en) 2015-09-24
AU2015233006A1 (en) 2016-11-03
US20180233823A1 (en) 2018-08-16
MX371276B (en) 2020-01-23
PT3119201T (en) 2018-06-15
US20170049776A1 (en) 2017-02-23
EP3372083A1 (en) 2018-09-12
SI3119201T1 (en) 2018-07-31
EP3119201A2 (en) 2017-01-25
NO2723977T3 (en) 2018-03-10
EP3119201A4 (en) 2017-03-15
CL2016002318A1 (en) 2017-03-24
EP3119201B1 (en) 2018-03-14
JP2017508764A (en) 2017-03-30
US9968609B2 (en) 2018-05-15
PL3119201T3 (en) 2018-08-31
CN106132204B (en) 2019-08-20
WO2015140748A3 (en) 2015-12-17
AU2018250378A1 (en) 2018-11-08
JP6744821B2 (en) 2020-08-19
RS57206B1 (en) 2018-07-31
CN106132204A (en) 2016-11-16
EA201691871A1 (en) 2017-03-31
MX2016012154A (en) 2016-12-15
US10211534B2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
NZ729678A (en) Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
AU366476S (en) Bottle
SG10201808038TA (en) Sildenafil Solutions and Methods of Making and Using Same
GB2538406A (en) Treatment fluids for reducing subterranean formation damage
MX2017008414A (en) Nitrification inhibitor compositions and methods for preparing the same.
GB2540096A (en) Liquid concentrate of a strength retrogression additive
AU362552S (en) Swimsuit water extractor
GB2537519A (en) Magnesium metal ore waste in well cementing
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
PH12016502311A1 (en) Omega-3 analogues
MX2016005473A (en) Methods and compositions for improving kidney function.
MX2019000677A (en) B-cell-mimetic cells.
NZ727292A (en) Methods of treating incontinence and other sphincter deficiency disorders
CL2017000690A1 (en) New iron (III) hydroxide complex with activated glucose syrups and preparation procedure
MX2019004179A (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease.
PH12017500391B1 (en) A process for producing iron (iii) casein n-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions
WO2017116903A8 (en) Method of preparing diaminophenothiazinium
MY188557A (en) Lipid comprising docosapentaenoic acid
AU201615391S (en) Dummy/pacifier
GR1008534B (en) Olive preparation, processing and preservation with mineral himalaya salt
IN2014MU00664A (en)
RS20160314A1 (en) The spiral-conical strainer
TH172001B (en) Sildenafil solution And production methods and use the same